探讨FDG PET/CT最大标准摄取值（SUVmax-M）对原发性转移性鼻咽癌（mNPC）患者在姑息化疗和局部区域放疗（LRRT）后的预后作用。我们回顾性收集了2012年1月至2020年10月之间86名符合条件的患者的信息。评估了所有涉及SUVmax和血清乳酸脱氢酶（LDH）诊断参数，通过最大对数秩和方法确定了截断值。多元分析使用Cox比例风险回归进行，以识别与总生存率（OS）相关的独立预后因素。所有估计的生存率是用Kaplan-Meier方法进行的。该队列的中位生存时间和进展时间分别为38.2和13.9个月。单因素分析显示，男性、转移部位≥4、肝脏是否受累、血清LDH≥229、SUVmax-M≥10、SUVmax-M-sum≥10和SUVmax-M-mean≥8.8是显著的预后因素。经过LASSO回归后确定了五个变量并进入多元分析。此外，肝脏受累（P = 0.039）、LDH升高（≥229）（P = 0.05）和更高的SUVmax-M（≥10）（P = 0.004）与较差的OS显著相关。在姑息化疗和LRRT后治疗的原发性转移性鼻咽癌患者中，转移灶高SUVmax（≥10）、肝脏受累和诊断时血清LDH升高（≥229）可以独立预测较差的生存率。©2023年作者（们）。

To explore the prognostic role of FDG PET/CT maximal standard uptake values of metastatic lesions (SUVmax-M) in patients with de novo metastatic nasopharyngeal carcinoma (mNPC) following palliative chemotherapy and locoregional radiotherapy (LRRT).We retrospectively collected the information of 86 eligible patients between Jan 2012 and Oct 2020. All the parameters involving SUVmax and serum lactate dehydrogenase (LDH) at diagnosis were evaluated and cutoff values were determined by the maximum log-rank statistic method. The multivariate analysis was performed using Cox proportional hazards regression to identify the independent prognostic factors associated with overall survival (OS). All estimated survival rates were conducted with Kaplan-Meier method.Median survival and progression time in the cohort were 38.2 and 13.9 months, respectively. The univariable analysis showed that male, number of metastatic sites ≥ 4, presence of liver, serum LDH ≥ 229, SUVmax-M ≥ 10, SUVmax-M-sum ≥ 10, and SUVmax-M-mean ≥ 8.8 were significant prognostic factors. Five variables were identified after LASSO regression and entered into the multivariate analysis. Furthermore, liver involvement (P = 0.039), elevated LDH (≥ 229) (P = 0.05) and higher SUVmax-M (≥ 10) (P = 0.004) were significantly associated with worse OS.The high SUVmax of metastatic lesions (≥ 10), liver involvement, and elevated serum LDH (≥ 229) at diagnosis could independently predict poor survival for de novo mNPC patients treated with palliative chemotherapy following LRRT.© 2023. The Author(s).